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Abstract
Purpose: To identify the continual diversity between flattening photon beam (FB) and Flattening Filter Free (FFF) photon
beams for localized prostate cancer; and to determine potential benefits and drawbacks of using unflattened beam for this type
of treatment. Methods: Eight prostate cases including seminal vesicles selected for this study. The primary planning target vol-
ume (PTVP) and boost planning target volume (PTVB) were contoured. The total prescription dose was 78 Gy (56 Gy to PTVP
and an additional 22 Gy to PTVB). For all cases, treatment plans using 6MV with FB and FFF beams with identical dose-volume
constraints, arc angles and number of arcs were developed. The dose volume histograms for both techniques were compared for
primary target volume and critical structures. Results: A low Sigma index (FFF: 1.65 + 0.361; FB: 1.725 + 0.39) indicating im-
proved dose homogeneity in FFF beam. Conformity index (FFF: 0.994 + 0.01; FB: 0.993 + 0.01) is comparable for both tech-
niques. Minimal difference of Organ at risk mean dose was observed. Normal tissue integral dose in FB plan resulted 1.5% lower
than FFF plan. All the plans displayed significant increase (1.18 times for PTVP and 1.11 for PTBB) in the average number of
necessary MU with FFF beam. Conclusion: Diversity between FB and FFF beam plans were found. FFF beam accelerator has
been utilized to develop clinically acceptable Rapid Arc treatment plans for prostate cancer with 6 MV.
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Introduction
Cancer is the major cause of leading deaths in the 21st century
in world with 14.1 million cases and 8.2 million deaths oc-
curred in 2012.1Among them, prostate cancer stands as im-
portant due to risk of secondary malignancies associated with
intensity modulation radiation therapy (IMRT) with con-
ventional 3-Dimentional conformal radiotherapy (3D-CRT).2
Among the different technologies adopted, to cure the pros-
tate cancer; External radiotherapy is recognized as one of the
important treatment option.3-4 The technology aims to de-
stroy cancer cells by minimal damaging (due to risk of sec-
ondary malignancies) to the surrounding normal tissues. It
creates a best possible balance between maximizing dose to
prostate cancer cells and minimization of side effects. Inten-
sity-modulated radiotherapy (IMRT) technology for localized
intermediate risk prostate tumor/cancer allows less toxicity in
comparison to 3D-CRT.5
Among the external beam radiotherapy techniques; Rapid
Arc (Varian Medical Systems, Palo Alto) is a volumetric ra-
diotherapy technology that delivers a fast and precise
sculpted 3D dose distribution with a single 360-degree rota-
tion of the linear accelerator gantry to improve the standard
of care and treatments.6 It is made possible by a treatment
planning algorithm that simultaneously changes
3-parameters during treatment by a) tuning rotation speed of
the gantry; b) shape of the treatment aperture using the
movement of multileaf collimator leaves; and c) delivery dose
rate. Volumetric modulated arc therapy differs from existing
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techniques like helical IMRT or intensity-modulated arc
therapy (IMAT) because it delivers dose to the whole volume,
rather than segment by segment. The treatment planning
algorithm ensures the treatment precision, helping to spare
normal healthy tissue.7 Rapid arc, represented by the True
beam STx linear accelerator (Varian Medical Systems, Palo
Alto) is an alternative volumetric modulated arc therapy
technique. The treatment machine True beam STx, which is
capability of wide spectrum of conformal treatment tech-
niques like conformal beam static conformal arc, dynamic
conformal arc, multiple choice IMRT and is capability of
delivery of both flatten beam (FB) and flattening filter free
(FFF) beams.8
Traditionally, the flattening filter in the X-ray beam path of a
linear accelerator produce an almost uniform fluence over a
collimated field. The removal of flattening filter leads to
radially decreasing fluence distribution and thus to
non-homogeneous dose distribution. Its positive influence on
the peripheral dose has an advantage of reduced head scatter
and MLC leakage, as well as a considerable increasing in the
dose rate, which has a beneficial effect on modern therapy
methods.9 To improve shielding in the treatment head; Hall et
al. suggested the use of secondary jaws to track the MLC and
removal of the flattening filter as a source of scattered radia-
tion in IMRT. The disadvantage of non-uniform, conical
fluence distribution could be taken into account with inten-
sity modulation radiation therapy (IMRT) in the optimization
algorithm.
The present study aims to identify the main and continual
diversity between flattened photon beam (FB) and Flattening
Filter Free (FFF) photon beams using Eclipse treatment
planning system and True Beam STx linear accelerator for
localized prostate cancer. Subsequently; the study explores
the potential benefits for determining the possibility to de-
velop clinically acceptable Rapid Arc treatment plans for
prostate cancer with 6 MV. This may reduce secondary ma-
lignancies without sacrificing local control or increasing
toxicity rates.10
Methods and Materials
A total of eight patients have been selected for treatment with
external beam radiation therapy for localized prostate cancer
analysis. This study includes prostate with seminal vesicles as
target. Computed Tomography (CT) images were acquired
with an empty rectum and full bladder for all patients and
imported to the Eclipse treatment planning system, version
10.0.26 (Varian Medical Systems, Palo Alto, CA) and regis-
tered. The attending radiation oncologist manually seg-
mented prostate and seminal vesicles based on CT images.
The primary planning target volume (PTVP) was defined to
include 0.7 cm margin around the prostate and seminal vesi-
cles in all directions except the posterior direction, where 0.5
cm margin was added. The boost planning target volume
(PTVB) was defined to include 0.7 cm margin around the
prostate in all direction except the posterior; where 0.5 cm
margin was added. All of the prostate patients at our institute
were treated with image-guidance; based on measured local-
ization uncertainties such as inter-user reproducibility and
intra-fraction motion.11 Rectum, Bladder, Bowel and left and
right femoral head were contoured as Organ At Risk(OARs)
based on CT images. Both FB and FFF beams were developed
for each patient in the eclipse treatment planning system
using 6 MV photons in a Varian made True Beam STx ma-
chine; having dynamic capability of 120 high definition MLC.
The anisotropic analytical algorithm (AAA, version 10.0.26)
has been used.12-13 Dose grid sizes of (3 × 3 × 3) mm3 were used
throughout the study. The slice thickness of the CT images
used for planning purpose was 3 mm. The total prescription
dose was 78 Gy in 39 fractions. The prescription dose of the
primary plans was 56 Gy to PTVP and prescription dose of the
boost plans was 22 Gy to PTVB following the Radiation
Therapy Oncology Group (RTOG) 0521 protocol.
A primary plan for PTVP and separate plan for PTVB were
generated using FB and FFF beam for each patient. All the
patients’ image sets were chosen in such way that, there was
not much variation in anatomy. All the patients’ anteri-
or-posterior (AP) and lateral separations were very close. The
average AP diameter was 21 cm and the lateral diameter was
32 cm. The average volume of PTVP and PTVB were 197.68 cc
(range, 169.8-239.3 cc) and 147.66 cc (range, 101.2 cc-166.9
cc) respectively. The average volume of bladder, rectum, right
femoral head, left femoral head and Bowel were 211.36 cc
(range, 64.6 cc-371.7 cc), 79.93 cc (range, 55.5 cc-114.5 cc),
164.34 cc (range, 141.9 cc-211.5 cc), 163.95 cc (range, 141.2
cc-212.5 cc) and 1243.9 cc (range, 380 cc-1680 cc) respec-
tively. Two arcs (182o to 178o; 178o to 182o) were used in both
clock wise and anti-clock wise directions for all patients in
treatment planning. For the clock wise arc, the collimator was
rotated 20o while for the anti-clockwise arc; the collimated
was rotated 340o in order to reduce the effect due to inter-leaf
leakage. All plans were generated using Eclipse planning
system (version 10.0.26) and the volumetric dose optimiza-
tion method followed the same systematic strategy regarding
the objective and priorities. The optimization constraints for
all plans are listed in Table 1. These constraints and weight-
ings were set initially and then modified by either relaxing or
tightening during the optimization process based on the re-
al-time updated dose-volume histograms (DVHs) of struc-
tures. Figure 1 is showing a transversal view of rapid arc plan
setup using two arcs and the PTVp.
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FIG. 1: A transversal view of rapid arc plan setup using two Arcs and the Primary target volume (PTVp.)
Treatment plan was done based on the radiotherapy objective
of delivering a therapeutic dose to a well-defined target while
minimizing dose to the surrounding normal tissue and critical
organs. It requires optimization of conformity of the pre-
scription dose to the planning target volume, dose homoge-
neity within the PTV and dose to the surrounding normal
tissue and critical organs. The following parameters were
evaluated for comparing cumulative dose volume histogram
of the patient such as Sigma-index, conformity index, mean
doses to bladder, rectum, bowel, right femoral head and left
femoral head.
The better representation of homogeneity could be defined in
term of sigma index (S-index).14 This uses the differential
DVH, unlike other indices, which is cumulative DVH.
S-index is a measure of the standard deviation of the doses
about the mean dose. The S-index is expressed as follow.
i
SD i mean
vS index D (D D ) V    
Dmean is the mean dose of the target (PTV in this study) curve.
Di is dose to the ith bin having a volume vi. V = total volume of
the target.
The conformity index (CI) was defined to compare the
treatment plans. The conformity index is defined as the ratio
of the 95% isodose volume divided by the PTV that is en-
closed by the 95% of the isodose line. From this definition, as
the conformity index approaches 1, the more conformal is the
treatment plan.
Dose distribution, PTV coverage and organs at risk.
In addition to providing information on the homogeneity of
radiation doses; DVHs can also be used to assess target cov-
erage index, defined as the percentage of the tumor volume
that received the prescribed dose. Ideally; tumor DVH would
be a step function, with 100% of the target receiving the exact
prescribed dose. However, actual DVH curves are not step
functions, because of constraints imposed by tumor volume
and other organs at risk (OAR). Rules for PTV was set such
that the prescribed dose covered at least 95% of the PTV (D95)
and the PTV volume receiving > 107% of the prescription was
limited to 2% in line with ICRU report 50 and ICRU report
62. To achieve this objective, a constraint for D100 was set to
receive ≥ 98% of prescription and constraint for maximum
dose (Dmax) was set to receive ≤ 102% of the prescription in
the optimization process for both plans. For all of the cases,
treatment plans using 6 MV with maximum dose rate of 600
MU/min for FB beams and 1,400 MU/min for FFF beams were
developed under identical conditions such as dose-volume
constraints, arc angle and number of arcs.
The volumes that received a minimum of 50 Gy, 60 Gy, 65
Gy, 70 Gy, 75 Gy (V50Gy, V60Gy, V65Gy, V70Gy, V75Gy) for rectum,
65 Gy, 70 Gy, 75 Gy, 80 Gy (V65Gy, V70Gy, V75Gy, V80Gy) for
bladder and 45 Gy, 15 Gy (V45Gy, V15Gy) for bowel  respec-
tively, were selected to evaluate volumes of high dose.15-16
Normal Tissue Integral Dose and MU
The integral dose (in unit of liter-Gy) was defined as the
absorbed dose integrated over the voxels in the entire volume
excluding PTV. The integral dose (ID) (mean dose × tissue
volume) received by normal tissue (NTID) was calculated
from dose-volume histograms. For comparison, the integral
dose ratio was obtained by dividing the integral dose from a
FB plan by the integral dose from FFF plan. MU was analyzed
for FFF and FB plans and reported.
Statistical Analysis
Statistical analysis was performed with Statistical Analysis
Software (SAS), version 9.3. Mean values and standard devia-
tion of the mean (SD) were collected. Relative dosimetric
changes were compared applying the paired t-test. A
two-sided p value ≤ 0.05 was considered statistically signifi-
cant. Confidence intervals (CI) included 95% of the measured
data.
Results
Sigma index (S-index) and Conformity index (CI)
The S-index and conformity indices for all the prostate pa-
tients in the both FB and FFF beam with 6 MV photons are
summarized in Table 2-3. The relative efficacy (FB/FFF)
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values for, S-index and conformity index are 1.045.0.998 for
PTVP and 1.113, 0.999 for PTVB respectively. The transversal
view of comparative dose distribution between FB plan and
FFF beam plans is shown in Figure 2.
Dose distribution, PTV coverage and organs at risk
Two typical dose-volume histograms for 6-MV plans, with
and without a flattening filter, are compared in Figure 3-5.
The PTV coverage was more uniform in the plans with un-
flattened beams.
FIG. 2: Transversal view of comparative dose distribution between FB plan (Lt side) and FFF beam plans (Rt side). Here 100% considered 78Gy
(composite plan).
TABLE 1: Dose-Volume constraints and relative weightings used for optimization of both FB and FFF Rapid Arc plans.
PTVs and OARs Dose-Volume constraints Relative weighting
PTVP and PTVB D100≥98%; Dmax≤102% 110-120
Rectum and Bladder V70%≤30%; V50%≤50%; V30%≤70%; D5-D10≤total
of 60-70Gy; Dmax≤100%
60-80
Bowel V50%≤30%; V30%≤50%; V10%≤70%;
Dmax≤total of 45 Gy
50-60
Femoral heads V20%-V30%≤30%; Dmax≤total of 45 Gy 50-60
TABLE 2: S- index and conformity index of PTVP plans for FB and FFF beam.
FB FFF beam
Pt.No. S-index CI S-index CI
1 1.9 0.991 1.8 0.992
2 2.4 0.97 2.4 0.971
3 1.9 0.998 1.8 0.999
4 1.7 0.999 1.7 0.999
5 1.9 0.987 1.6 0.993
6 1.7 0.999 1.4 0.999
7 1.2 .0999 1.4 0.998
8 1.1 0.999 1.1 0.999
Mean±SD 1.725±0.39 0.993±0.01 1.65±0.361 0.994±0.01
TABLE 3: Sigma indices and conformity index of PTVB plans for FB and FFF beam.
FB FFF beam
Pt.No. S-index CI S-index CI
1 1.9 0.992 1.8 0.993
2 2.4 0.98 2.4 0.981
3 1.6 0.998 1.6 0.998
4 1.7 0.992 1.7 0.993
5 1.7 0.995 1.3 0.998
6 1.5 0.999 1.2 1
7 1.9 0.998 1.3 0.998
8 1 0.999 1 0.999
Mean±SD 1.713±0.372 0.994±0.006 1.538±0.413 0.995±0.006
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TABLE 4: Mean dose statistics (with SD) of Organ at risk for composite plan.
Structure
Dose-Volume
constraints Volume achieved in %
FB FFF P
Rectum V50Gy < 50% 29.82±5.9% 28.62±4.4% 0.239
V60Gy < 35% 20.08±4.1% 19.35±3.0% 0.244
V65Gy < 25% 16.04±3.3% 15.65±2.6% 0.382
V70Gy < 20% 12.4±2.9% 12.2±2.4% 0.538
V75Gy < 15% 8.42±2.8% 8.52±2.4% 0.633
Bladder V65Gy < 50% 19.26±10.2% 18.17±9.4% 0.425
V70Gy < 35% 14.84±7.4% 15.02±7.7% 0.135
V75Gy < 25% 11.74±5.6% 11.9±5.8% 0.301
V80Gy < 15% 3.36±3.97% 3.50±3.4% 0.736
Bowel V45Gy < 195cc 0.48±1.08% 0.48±1.09% 0.801
V15Gy < 120cc 4.79±7.72% 4.73±7.62% 0.276
Rt Femoral Head V50Gy < 5% 0.0±0.0% 0.0±0.0% -
Lt Femoral Head V50Gy < 5% 0.0±0.0% 0.0±0.0% -
TABLE 5: Average Maximum dose statistics (with SD) and average dosimetric indices (With SD) of PTV and Organ at risk for composite plan.
Structure Mean Dose in Gy Maximum Dose in Gy
FB FFF P FB FFF p
PTV 79.56±0.82 79.64±0.72 0.303 82.48±0.94 82.38±1.17 0.675
Rectum 37.46±4.75 37.46±4.59 1.000 80.99±1.46 81.18±1.28 0.417
Bladder 37.7±11.86 37.9±12.02 0.203 81.99±0.56 81.69±0.66 0.873
Bowel 3.0±2.89 3.08±2.84 0.047 30.7±24.2 30.3±23.6 0.301
RT FH 15.71±1.88 15.96±1.82 0.083 35.09±4.44 34.86±5.13 0.467
LT FH 15.94±1.85 16.04±1.97 0.170 37.38±4.39 37.29±4.52 0.531
For the rectum; there was no dose differences between the
two treatment modalities in the volume exposed to 60 Gy, 65
Gy, 70 Gy and 75 Gy. Only small difference was observed for
the volume exposed to 50 Gy which is not statistically sig-
nificant (p = 0.239). In case of bladder; there were no dose
differences for the volume exposed to 70 Gy, 75 Gy and 80 Gy
but small difference was noted for the volume exposed to 65
Gy, which is statistically insignificant (p = 0.424). For the
bowel; there was no significant dose differences between the
two treatment modalities in the volume exposed to 45 Gy or
15 Gy and femoral heads were within the required constraints
for all patients. Table 4 shows mean dose statistics with
standard deviation of organ at risk for composite plan.
Table 5 shows average maximum dose statistics (with SD) and
average dosimetric indices with standard deviation of PTV
and organ at risk for composite plan. No significant differ-
ences were noted between FB and FFF beam plans in the
average doses delivered to the bladder, rectum, and femoral
heads. A significant increase in mean dose of 2.6% (p < 0.047,
95% CI = 0.001 to 0.149) to the bowel was measured for FFF
beam plans compared with FB plans. The average maximum
dose of PTV is 105.74% and 105.62% of prescribe dose for
both FB and FFF beam plans respectively. No significant
differences between two modalities were observed with re-
spect to mean average maximum dose to bladder, rectum,
femoral heads and bowel.
Normal tissue integral dose and MU
Because of radiation could induce second malignancies, 2
integral dose was used as an index to compare techniques for
radiation induced second cancers. The NTID (mean ± SD) was
125.1 ± 23.57 liter-Gy for FB plan and 126.98 ± 24.14 liter-Gy
for FFF beam. FFF beam delivered 1.50% more dose com-
pared with the FB beam (p < 0.002, 95% CI = -2.775 to
-0.985). Comparison of the integral dose for FB and FFF beam
in Rapid Arc composite plans is shown in Figure 6. For flat-
tened beam-intensity modulation treatments, including
IMRT and Rapid Arc, the number of MU needed are an in-
dicator for the mean body dose.17 We found that MU (mean ±
SD) was 675 ± 36.66 for FB plans and 796 ± 88.11 for FFF
beam plans in PTVP. MU (mean ± SD) was 615 ± 80.29 for FB
plans and 683 ± 94.34 for FFF plans in PTVB. Compared with
FB plan, the MU significantly increased by 17.9 % (p < 0.003,
95% CI = -188.3 to -54.44) in PTVP and 11.05 % (p < 0.004,
95% CI = -103.9 to -33.087) in PTVB for FFF beam plan.
Discussion
These Indices clearly represent more homogeneous dose for
FFF beam plan than for the FB plans. The measured data
found is in accordance with reported values by Yoon et al.
The lower the value of S-index indicates the better is the
homogeneity (Table 2-3). From our data between FFF and FB
plans, FFF beam plans are showing lower S-indices for both
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PTVP and PTVB plans indicating improved dose homogeneity
compared to FB plans.
Miften et al.18have demonstrated the use of target conformity
index (TCI) and normal tissue-sparing index (NTSI) to assist
in the process of judging the merit of a clinical treatment
plan. But, in this work, the widely accepted conformity index
was used to evaluate the conformity of the treatment plans
(Table 2-3) for all the patients using both techniques. The
mean conformity index was 0.993 & 0.994 for PTVP and 0.994
& 0.995 for PTVB (FB & FFF) beam plans respectively. These
small differences indicate that these plans are nearly identical
in their conformity of dose to the target.
Vassiliev et al.19 reported in their planning study with and
without flattening filter, similar treatment plans regarding
PTV coverage for prostate cancer. Depending on the beam
energy, 6MV FFF beam produced superior IMRT plans than
6MV FB.20 However, plans and treatment delivery parameters
were not fully optimized for FFF beams. The improvement of
PTV coverage for either plan might have been possible with
different user-specific cost functions for both the PTV and
organ at risk been reported. A negligible difference in PTV
coverage between flattened and FFF beams IMRT prostate
plans has been observed by Stathakis et al.21 A similar results
have been reported by Zwahlen et al;22 using 6MV hypo
fractionated volumetric modulated arc therapy with and
without flattening filter got similar results regarding PTV
coverage for prostate cancer.
FIG. 3: Comparison of the dose -volume histograms for FB (square) and FFF beam (triangle) for PTVP Rapid Arc plan.
FIG. 4: Comparision of the dose -volume histograms for FB (square) and FFF beam (triangle) for PTVB Rapid Arc plan.
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FIG. 5: Comparision of the dose -volume histograms for FB (triangle) and FFF beam (square) for PTV78Gy and OARs in Rapid Arc composite plan.
FIG. 6: Comparison of the integral dose for FB and FFF beam in Rapid Arc composite plans.
FIG. 7: Comparison of the MUs for FB and FFF beam for PTVP Rapid Arc plans. PTVP FB is the primary planning treatment volume Flattened
Beam plans and PTVP FFF is the primary planning treatment volume Flattening Filter-Free beam plans.
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FIG. 8: Comparison of the MUs for FB and FFF beam for PTVB Rapid Arc plans. PTVBFB is the Boost planning treatment volume Flattened Beam
plans and PTVB FFF is the Boost planning treatment volume Flattening Filter-Free beam plans.
The increased NTID can be attributed to the softer photon
spectrum and resultant higher skin dose from FFF beams.
Therefore, it does not necessarily indicate higher doses are
required to internal organs. Moreover, it is possible to reduce
the skin dose by increasing beam energy.23
The average number of necessary MU with the use of FFF
beams is shown in Figure 7-8. Because of larger treatment
fields, the dose uniformity within an irradiated treatment
field will need to be “modulated” by MLC movements (IMRT)
to cut down the higher beam intensity near the central por-
tion of the FFF X-ray beam. Thus, larger MUs are required
compared to a conventional (flattened) X-ray beam. MLC
movements (IMRT) are now being used to flatten the FFF
X-rays to provide dose uniformity within those large PTVs.
The high dose rates from the FFF X-rays are now being off-set
by the larger MUs requirements. Zwahlen et al. reported
similar results as we found here. In contrary, Vassiliev et al.
and Stathakis et al. found a significant decrease in the number
of MU for their FFF treatment plans. The reason was that our
FFF beams were calibrated in order that 100MU corre-
sponded to 1Gy at the depth of maximum dose, as this was
common for flattened beam.24
However, for all prototype LINACs with FFF capabilities used
by other groups, only the flattened beams were calibrated.
This resulted in a higher dose per 100 MU for the unflattened
beams. Therefore they report a decrease in number of MU
that we could not confirm in our study. Our data demon-
strated that the mean body dose slightly decreased with the
mean energy of the beam, despite the increase in number of
MU that did not affect the mean body dose. From our study;
we did not found beam on time difference between these
techniques. The time advantage increased when using higher
dose per fraction. However, was insignificant for standard
fractionation of 2Gy.25
Conclusion
For treatment plans with Rapid Arc, FFF beams resulted in
dose distribution similar to flattened beams. No significant
differences were found between FFF and FB plans in the
mean dose and maximum dose of bladder and rectum. Bowel
and femoral heads being at a clinically significant distance
from PTVs (Prostate and seminal vesicles) usually experience
small doses. Sigma indices are lower, which correspond to
lower HI in FFF beam plans, indicating improved dose ho-
mogeneity for both PTVP and PTVB. No dose constraints
violation occurred for both the techniques. Plans with FFF
beams tend to have comparable conformity and higher NTID
than plans with FB beams. The increased NTID can be at-
tributed to the softer photon spectrum and resultant higher
skin dose from FFF beams. Therefore, it does not necessarily
indicate higher skin doses to internal organs. Though the
differences were insignificant, using a FFF beam accelerator;
26 it has been possible to develop clinically acceptable Rapid
Arc treatment plans for prostate cancer with 6 MV.
Conflict of interest
The authors declare that they have no conflicts of interest.
The authors alone are responsible for the content and writ-
ing of the paper.
References
1. Ferlay J, Soerjomataram I, Ervik M, et
2. Hall EJ. Intensity-modulated radiation therapy,
protons, and the risk of second cancers. Int J Radiat
Oncol Biol Phys 2006; 65:1-7.
3. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implica-
tions of the rapid adoption of newer technologies
 al.  GLO-
BOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC Cancer Base No. 11 2013. Lyon,
France: International Agency for Research on
Cancer. Available from http://globocan.iarc.fr
Volume 2 • Number 4 • 2014 International Journal of Cancer Therapy and Oncology 9
www.ijcto.org
© Rout et al. ISSN 2330-4049
for treating prostate cancer. J Clin Oncol 2011;
29:1517-24.
4. Rukstalis DB. Treatment options after failure of ra-
diation therapy-a review. Rev Urol 2002; 4 Suppl
2:S12-7.
5. Heidenreich A, Bolla M. Joniau S, et al. Guidelines
on Prostate Cancer; European Association of Urol-
ogy 2011
6. Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy
treatment plans with RapidArc for prostate cancer
involving seminal vesicles and lymph nodes. Int J
Radiat Oncol Biol Phys 2010; 76:935-42.
7. Seppala J, Suilamo S, Kulmala J, et al. A dosimetric
phantom study of dose accuracy and build-up ef-
fects using IMRT and RapidArc in stereotactic irra-
diation of lung tumours. Radiat Oncol 2012; 7:79.
8. Wiant DB, Terrell JA, Maurer JM, Yount CL,
Sintay BJ. Commissioning and validation of Brain-
LAB cones for 6X FFF and 10X FFF beams on a
Varian TrueBeam STx. J Appl Clin Med Phys
2013;14:4493.
9. Georg D, Knoos T, McClean B. Current status and
future perspective of flattening filter free photon
beams. Med Phys 2011; 38:1280-93.
10. Sun M, Ma L. Treatment Exceptionally large pros-
tate cancer patients with low energy intensity
modulated photons. J Appl Clin Med Phys 2006;
7:43-9.
11. Orton NP, Tome WA. The impact of daily shifts on
prostate IMRT dose distribution. Med Phys 2004;
31:1-4.
12. Bragg CM, Windate K, Conway J. Clinical imple-
mentations of the anisotropic analytical algorithm
for IMRT treatment planning and verification.
Radiother Oncol 2008; 86:276-84.
13. Lu, L. Dose calculation algorithms in external beam
photon radiation therapy. Int J Cancer Ther Oncol
2013; 1:01025.
14. Yoon M, Park SY, Shin D, et al. A new homogene-
ity index based on statistical analysis of the
dose-volume histogram. J Appl Clin Med Phys
2007; 8:9-17.
15. Lawrence BM, Ellen DY, ANDREW J, et al. Use of
normal tissue complication probability model in
the clinic. Int J Radiat Oncol Biol Phys 2010; 76:
S10–S19.
16. Michalski JM, Purdy JA, Winter K, et al. Prelimi-
nary report of toxicity following 3D radiation
therapy for prostate cancer on 3DOG/RTOG 9406.
Int J Radiat Oncol Bio Phys 2000; 46:391–402.
17. Followill D, Geis P, Boyer A. Estimates of
whole-body dose equivalent produced by beam in-
tensity modulated conformal therapy. Int J Radiat
Oncol Biol Phys 1997; 38:667-72.
18. Miften MM, Das SK, Su M, Marks LB. A
dose-volume based tool for evaluating and ranking
IMRT treatment plans. J Appl Clin Med Phys 2004;
5:1-14.
19. Vassiliev ON, Titt U, Ponisch F, et al. Dosimetric
properties of photon beams from a flattening filter
free clinical accelerator. Phys Med Biol 2006;
51:1907-17.
20. Vassiliev ON, Kry SF, Kuban DA, et al. Treat-
ment-planning study of prostate cancer intensi-
ty-modulated radiotherapy with a Varian clinic
operated without a flattening filter. Int J Radiat
Oncol Biol Phys 2007; 68:1567-71.
21. Stathakis S, Esquivel C, Gutierrez A, et al. Treat-
ment planning and delivery of IMRT using 6and
18MV photon beams without flattening filter. Appl
Radiat Isot 2009; 67:1628-37.
22. Zwahlen DR, Lang S, Hrbacek J, et al. The use of
photon beams of a flattening filter-free linear ac-
celerator for hypofractionated volumetric modu-
lated arc therapy in localized prostate cancer. Int J
Radiat Oncol Biol Phys 2012; 83:1655-60.
23. Aoyama H, Westerly DC, Mackie TR, et al. Integral
radiation dose to normal structures with conformal
external beam radiation. Int J Radiant Oncol Biol
Phys 2006; 64:962-967.
24. Almond PR, Biggs PJ, Coursey BM, et al. AAPM’s
TG-51 protocol for clinical reference dosimetry of
high-energy photon and electron beams. Med Phys
1999; 26:1847-70.
25. Fu W, Dai J, Hu Y, et al. Delivery time comparison
for Intensity-modulated radiation therapy with/
without flattening filter: A planning Study. Phys
Med Biol 2004; 49:1535-47.
26. Lang S, Reggiori G, Puxeu Vaquee J, et al. Pre-
treatment quality assurance of flattening filter free
beams on 224 patients for intensity modulated
plans; a multicentric study. Med Phys 2012;
39:1351-6.
